Remoxipride in acute psychosis: Intramuscular followed by oral treatment compared to haloperidol, a doubleblind, multicenter trial

Jp, Kahn; Laxenaire, M.C.; Burnat, Grzegorz; Albaret, C.; Holm, A.-C.

doi:10.1002/hup.470090201

Cited by 4 publications

(2 citation statements)

References 13 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose of 20 mg haloperidol is certainly at the upper limit of the therapeutic range but this was considered acceptable, given the selection of acutely exacerbated psychotic patients and the possibility to decrease dose if necessary; this dose had been used in similar clinical studies (van Putten et al 1990;Conley et al 1994;Kahn et al 1994;Chouinard 1995;Czobor et al 1995). Although there are conßicting results concerning the dose-dependent e¤ect of haloperidol on extrapyramidal symptoms, and data indicate that there is no further improvement obtained with doses higher than 10 mg/day (McEvoy et al 1991;Rifkin et al 1991), it cannot be excluded that the haloperidol dose used in this study may have led to bias in favour of amisulpride concerning the comparison of the safety proÞles.…”

Section: Discussionmentioning

confidence: 99%

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol

et al. 1997

View full text Add to dashboard Cite

Amisulpride is a substituted benzamide with high selectivity for dopaminergic D2 and D3 receptors. This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia. This multicenter, double-blind trial involved 191 patients allocated, after a 1 to 7-day wash-out period, to amisulpride (n = 95) or haloperidol (n = 96) for 6 weeks. Improvement of mean BPRS total score was 48% for amisulpride and 38% for haloperidol (NS), whereas improvement in the Negative PANSS subscale was greater in the amisulpride group (37%) compared to haloperidol (24%) (P = 0.038). CGI scores showed a higher number of responders in the amisulpride (62%) than in the haloperidol group (44%) (P = 0.014). More extrapyramidal symptoms measured with the Simpson-Angus scale were provoked in the haloperidol group (P = 0.0009). Amisulpride is at least as effective as haloperidol in the treatment of acute exacerbations of schizophrenia, and is more effective in the treatment of negative symptoms whilst causing less parkinsonism.

show abstract

Section: Discussionmentioning

confidence: 99%

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Dufresne, Valentino, & Kass, 1993). BPRS dimensional subscales may document treatment effects for patients who would otherwise appear unresponsive to treatment when such comparisons are limited to total scale scores (Freedman et al, 1998; Kahan, Laxenaire, Burnat, Albaret, & Holm, 1994; Rapaport et al, 1993; Varner, Chen, Swann, & Moeller, 2000; Yamada et al, 1997). Indeed, the demonstration of group differences by total scale score in a contrasted-groups or repeated measures analysis provides limited useful information, in that subsequent subscale analyses are necessary to document the dimensions underlying such a global difference or change (cf.…”

Section: Factor-derived Bprs Subscalesmentioning

confidence: 99%

New subscales for an anchored version of the Brief Psychiatric Rating Scale: Construction, reliability, and validity in acute psychiatric admissions.

Lachar

Bailley²,

Rhoades³

et al. 2001

Psychological Assessment

View full text Add to dashboard Cite

Attending psychiatrists completed an anchored version of the 18-item Brief Psychiatric Rating Scale (BPRS-A) based on admission and evaluation information on a total of 2,921 adult patients treated at 1 public sector acute psychiatric teaching hospital. Exploratory factor analysis was applied to a 6-month sample to construct 4 nonoverlapping subscales: Resistance, Positive Symptoms, Negative Symptoms, and Psychological Discomfort. Confirmatory factor analysis compared these new subscales to 3 other published subscale models using a second 6-month sample. Internal consistency, rater influence, and interrater agreement were estimated in separate studies. Discriminant validity was explored by comparison of diagnosis-based samples. Application of the BPRS-A as a debriefing instrument in the study of symptomatic change and the multiple challenges inherent in psychometric study of such a rating scale in realistic hospital practice are discussed.

show abstract

Psychomotor, Cognitive, Extrapyramidal, and Affective Functions of Healthy Volunteers During Treatment With an Atypical (Amisulpride) and a Classic (Haloperidol) Antipsychotic

Ramaekers

Louwerens²,

Muntjewerff³

et al. 1999

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

The primary objective of this study was to compare the objective and subjective effects of amisulpride with those of a classic antipsychotic, haloperidol, when both were given to healthy volunteers in representative therapeutic doses over 5 days. The secondary objective was to compare the effects of relatively low and high doses of amisulpride to confirm the suspected duality of its pharmacologic activity. Twenty-one subjects participated in the four-way, randomized, double-blind, crossover study with repeated daily doses of amisulpride 50 mg, amisulpride 400 mg, haloperidol 4 mg, and placebo. Subjects were institutionalized during treatment periods and were under 24-hour medical supervision. They underwent a series of psychomotor and cognitive tests 1 hour before and 3 and 6 hours after dosing on days 1 and 5. Their extrapyramidal disturbances and drug-related feelings were assessed at the end of each replication. Psychiatric interviews and ratings of depression, subjective well-being, and negative symptoms occurred on day 4. Amisulpride 50 mg had no significant effect on any parameter. Amisulpride 400 mg had several adverse effects on psychomotor and, although less severe, on cognitive performance on the fifth day only. Amisulpride 400 mg produced no significant extrapyramidal disturbances in the group as a whole, although it may have in some individual subjects. Also, it produced no signs of mental disturbances on clinical rating scales or during a structured psychiatric interview. Haloperidol ubiquitously impaired psychomotor and cognitive performance in a similar fashion after the first and the final doses. It produced extrapyramidal disturbances in nearly every subject, the most common being akathisia and the most severe, in the case of one individual, being acute dystonia. Unlike amisulpride, haloperidol produced a number of mental disturbances, the most noteworthy being negative symptoms. Amisulpride seems to be a well-tolerated drug. Its side effects should be much less troublesome to patients using the drug on a long-term basis than those of classic antipsychotics, like haloperidol.

show abstract

Remoxipride in acute psychosis: Intramuscular followed by oral treatment compared to haloperidol, a doubleblind, multicenter trial

Cited by 4 publications

References 13 publications

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol

New subscales for an anchored version of the Brief Psychiatric Rating Scale: Construction, reliability, and validity in acute psychiatric admissions.

Psychomotor, Cognitive, Extrapyramidal, and Affective Functions of Healthy Volunteers During Treatment With an Atypical (Amisulpride) and a Classic (Haloperidol) Antipsychotic

Contact Info

Product

Resources

About